JP2020089382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020089382A5 JP2020089382A5 JP2020009595A JP2020009595A JP2020089382A5 JP 2020089382 A5 JP2020089382 A5 JP 2020089382A5 JP 2020009595 A JP2020009595 A JP 2020009595A JP 2020009595 A JP2020009595 A JP 2020009595A JP 2020089382 A5 JP2020089382 A5 JP 2020089382A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- modified
- nucleoside
- wing
- antisense oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30246910P | 2010-02-08 | 2010-02-08 | |
| US61/302,469 | 2010-02-08 | ||
| US37163510P | 2010-08-06 | 2010-08-06 | |
| US61/371,635 | 2010-08-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018055560A Division JP6652984B2 (ja) | 2010-02-08 | 2018-03-23 | 対立遺伝子多様体の選択的低減 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020089382A JP2020089382A (ja) | 2020-06-11 |
| JP2020089382A5 true JP2020089382A5 (enExample) | 2020-11-12 |
Family
ID=44355846
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552932A Active JP6006120B2 (ja) | 2010-02-08 | 2011-02-08 | 対立遺伝子多様体の選択的低減 |
| JP2016078592A Active JP6316334B2 (ja) | 2010-02-08 | 2016-04-11 | 対立遺伝子多様体の選択的低減 |
| JP2018055560A Active JP6652984B2 (ja) | 2010-02-08 | 2018-03-23 | 対立遺伝子多様体の選択的低減 |
| JP2020009595A Pending JP2020089382A (ja) | 2010-02-08 | 2020-01-24 | 対立遺伝子多様体の選択的低減 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552932A Active JP6006120B2 (ja) | 2010-02-08 | 2011-02-08 | 対立遺伝子多様体の選択的低減 |
| JP2016078592A Active JP6316334B2 (ja) | 2010-02-08 | 2016-04-11 | 対立遺伝子多様体の選択的低減 |
| JP2018055560A Active JP6652984B2 (ja) | 2010-02-08 | 2018-03-23 | 対立遺伝子多様体の選択的低減 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US8957040B2 (enExample) |
| EP (3) | EP3321361B1 (enExample) |
| JP (4) | JP6006120B2 (enExample) |
| AU (3) | AU2011213562B2 (enExample) |
| CA (1) | CA2789005A1 (enExample) |
| DK (1) | DK2534248T3 (enExample) |
| ES (1) | ES2733708T3 (enExample) |
| IL (2) | IL221272A (enExample) |
| WO (1) | WO2011097643A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| JP6006120B2 (ja) | 2010-02-08 | 2016-10-12 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 対立遺伝子多様体の選択的低減 |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| WO2013022967A1 (en) * | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof |
| EP2839008A4 (en) * | 2012-03-12 | 2015-12-02 | Roche Innovation Ct Copenhagen As | COMPOSITIONS AND METHODS FOR MODULATING ATXN3 EXPRESSION |
| WO2013148260A1 (en) * | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| EP2839006B1 (en) * | 2012-04-20 | 2018-01-03 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| EP2906699A4 (en) | 2012-10-11 | 2016-06-08 | Ionis Pharmaceuticals Inc | OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF |
| EP4086347A3 (en) | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| US9909128B2 (en) * | 2012-11-15 | 2018-03-06 | The Regents Of The University Of California | Splice modulating oligonucleotides that inhibit cancer |
| ES2817050T3 (es) | 2013-02-04 | 2021-04-06 | Ionis Pharmaceuticals Inc | Compuestos antisentido selectivos y usos de los mismos |
| ES2807379T3 (es) | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Composiciones y métodos para regular la expresión de Tau |
| TW202246503A (zh) | 2013-07-19 | 2022-12-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3194597B1 (en) * | 2014-09-18 | 2021-06-30 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2016161388A1 (en) | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| US10533175B2 (en) | 2015-09-25 | 2020-01-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Ataxin 3 expression |
| EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| WO2017087282A1 (en) | 2015-11-18 | 2017-05-26 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease |
| US10370667B2 (en) | 2015-11-18 | 2019-08-06 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease |
| CN108697709A (zh) | 2015-12-10 | 2018-10-23 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| KR102604132B1 (ko) | 2015-12-14 | 2023-11-17 | 콜드스프링하버러보러토리 | 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| JP7749201B6 (ja) | 2016-01-31 | 2025-10-21 | ユニバーシティー オブ マサチューセッツ | 分岐オリゴヌクレオチド |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
| JOP20190104A1 (ar) * | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN110799647A (zh) | 2017-06-23 | 2020-02-14 | 马萨诸塞大学 | 双尾自递送sirna及相关的方法 |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| BR112020022512A2 (pt) | 2018-05-04 | 2021-05-04 | Stoke Therapeutics, Inc. | métodos e composições para tratamento de doença de armazenamento de éster de colesteril |
| WO2019217708A1 (en) | 2018-05-09 | 2019-11-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn3 expression |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| EP3833763A4 (en) | 2018-08-10 | 2023-07-19 | University of Massachusetts | MODIFIED OLIGONUCLEOTIDES FOR TARGETING SNPS |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| JP2022523467A (ja) | 2019-01-18 | 2022-04-25 | ユニバーシティ・オブ・マサチューセッツ | 動的な薬物動態を修飾するアンカー |
| US11820985B2 (en) | 2019-03-26 | 2023-11-21 | University Of Massachusetts | Modified oligonucleotides with increased stability |
| CN114502730A (zh) * | 2019-08-09 | 2022-05-13 | 马萨诸塞大学 | 经化学修饰的靶向snp的寡核苷酸 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| JP2023500251A (ja) | 2019-11-01 | 2023-01-05 | ノバルティス アーゲー | ハンチントン病の進行を遅らせる処置のためのスプライシングモジュレーターの使用 |
| WO2021178374A2 (en) * | 2020-03-05 | 2021-09-10 | Synerk Inc. | Compounds and methods for reducing apoe expression |
| CN115666659A (zh) | 2020-03-26 | 2023-01-31 | 马萨诸塞大学 | 稳定性增加的修饰的寡核苷酸的合成 |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| CA3210076A1 (en) * | 2021-01-29 | 2022-08-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating huntingtin |
| AU2022234522A1 (en) * | 2021-03-08 | 2023-10-26 | Les Laboratoires Servier | Antisense oligonucleotides for inhibiting alpha-synuclein expression |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| AU2024223513A1 (en) * | 2023-02-15 | 2025-09-18 | Ascidian Therapeutics, Inc. | Htt trans-splicing molecules |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6331617B1 (en) | 1996-03-21 | 2001-12-18 | University Of Iowa Research Foundation | Positively charged oligonucleotides as regulators of gene expression |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US6753422B2 (en) | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| AU777363B2 (en) | 1999-03-01 | 2004-10-14 | Nuvelo, Inc. | Methods for targeting RNA molecules |
| PT1178999E (pt) | 1999-05-04 | 2007-06-26 | Santaris Pharma As | Análogos de l-ribo-lna |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| AU4819101A (en) | 2000-04-13 | 2001-10-30 | University Of British Columbia, The | Modulating cell survival by modulating huntingtin function |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| US20030109476A1 (en) | 2001-08-07 | 2003-06-12 | Kmiec Eric B. | Compositions and methods for the prevention and treatment of Huntington's disease |
| US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| EP1560840B1 (en) | 2002-11-05 | 2015-05-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| JP4731324B2 (ja) | 2003-08-28 | 2011-07-20 | 武 今西 | Ｎ−ｏ結合性架橋構造型新規人工核酸 |
| EP2821085B1 (en) * | 2003-09-12 | 2020-04-29 | University of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
| WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
| US20050176045A1 (en) | 2004-02-06 | 2005-08-11 | Dharmacon, Inc. | SNP discriminatory siRNA |
| CA2568735A1 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| EP2397563A3 (en) * | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| EP2316967A1 (en) * | 2005-06-28 | 2011-05-04 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin gene. |
| EP2161038B1 (en) | 2006-01-26 | 2013-12-25 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
| ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
| WO2007136989A2 (en) | 2006-05-05 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of dgat2 |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
| EP2046993A4 (en) | 2006-07-07 | 2010-11-17 | Univ Massachusetts | RNA SILENCING COMPOSITIONS, AND METHODS OF TREATING HUNTINGTON CHOREA |
| JP5665317B2 (ja) | 2006-10-18 | 2015-02-04 | アイシス ファーマシューティカルズ， インコーポレーテッド | アンチセンス化合物 |
| JP2010510807A (ja) * | 2006-11-27 | 2010-04-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | 高コレステロール血症を治療するための方法 |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| WO2008143774A2 (en) | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
| WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| EP2014769B1 (en) | 2007-06-18 | 2010-03-31 | Commissariat à l'Energie Atomique | Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| CA2726866A1 (en) | 2008-05-09 | 2009-11-12 | The University Of British Columbia | Methods and compositions for the treatment of huntington's disease |
| WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| JP6006120B2 (ja) | 2010-02-08 | 2016-10-12 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 対立遺伝子多様体の選択的低減 |
| CA2789038A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP3173419A1 (en) | 2010-04-28 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom |
| EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| WO2013022967A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof |
| EP2839006B1 (en) | 2012-04-20 | 2018-01-03 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| PH12023550488A1 (en) | 2012-04-25 | 2024-06-24 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| EP2906699A4 (en) | 2012-10-11 | 2016-06-08 | Ionis Pharmaceuticals Inc | OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF |
| EP4086347A3 (en) | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| ES2817050T3 (es) | 2013-02-04 | 2021-04-06 | Ionis Pharmaceuticals Inc | Compuestos antisentido selectivos y usos de los mismos |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
| AU2019218987B2 (en) | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
-
2011
- 2011-02-08 JP JP2012552932A patent/JP6006120B2/ja active Active
- 2011-02-08 CA CA2789005A patent/CA2789005A1/en not_active Abandoned
- 2011-02-08 ES ES17206749T patent/ES2733708T3/es active Active
- 2011-02-08 AU AU2011213562A patent/AU2011213562B2/en active Active
- 2011-02-08 EP EP17206749.8A patent/EP3321361B1/en not_active Revoked
- 2011-02-08 WO PCT/US2011/024103 patent/WO2011097643A1/en not_active Ceased
- 2011-02-08 EP EP11740542.3A patent/EP2534248B1/en active Active
- 2011-02-08 DK DK11740542.3T patent/DK2534248T3/en active
- 2011-02-08 US US13/577,616 patent/US8957040B2/en active Active
- 2011-02-08 EP EP19164928.4A patent/EP3561060A1/en active Pending
-
2012
- 2012-08-02 IL IL221272A patent/IL221272A/en active IP Right Grant
-
2014
- 2014-12-23 US US14/581,235 patent/US20150329859A1/en not_active Abandoned
-
2016
- 2016-04-11 JP JP2016078592A patent/JP6316334B2/ja active Active
- 2016-09-28 AU AU2016234914A patent/AU2016234914B2/en active Active
-
2017
- 2017-08-28 IL IL254191A patent/IL254191B/en unknown
-
2018
- 2018-03-23 JP JP2018055560A patent/JP6652984B2/ja active Active
- 2018-04-24 US US15/961,567 patent/US20190002877A1/en not_active Abandoned
- 2018-11-07 AU AU2018260866A patent/AU2018260866A1/en not_active Abandoned
-
2020
- 2020-01-24 JP JP2020009595A patent/JP2020089382A/ja active Pending
-
2022
- 2022-01-18 US US17/577,832 patent/US12110491B2/en active Active
-
2024
- 2024-08-21 US US18/811,243 patent/US20250223589A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020089382A5 (enExample) | ||
| US12110491B2 (en) | Selective reduction of allelic variants | |
| JP7354342B2 (ja) | タウ発現を調節するための組成物 | |
| US10968453B2 (en) | Compositions for modulating SOD-1 expression | |
| JP6018506B2 (ja) | 対立遺伝子多様体の選択的低減 | |
| CN104968783B (zh) | 用于调节c9orf72表达的组合物 | |
| JP6606557B2 (ja) | Ｃ９ｏｒｆ７２発現を調節するための組成物 | |
| US10407678B2 (en) | Compositions for modulating expression of C9ORF72 antisense transcript | |
| US10793855B2 (en) | Compositions for modulating expression of C9ORF72 antisense transcript | |
| JP2013518604A5 (enExample) | ||
| CN105637090A (zh) | 用于调节c9orf72表达的组合物 | |
| CN106103717A (zh) | 用于调节共济失调蛋白2表达的组合物 | |
| CN104755621A (zh) | 癌症治疗 | |
| TW202134436A (zh) | 用於神經保護之方法及組成物 | |
| EP3366774A1 (en) | Nucleic acid complex having at least one bulge structure | |
| US12492399B2 (en) | Nucleic acid complex for regulating IHH expression | |
| WO2025206092A1 (ja) | Ｍｙｏｒｅｇｕｌｉｎ発現を調節するための化合物及び医薬組成物 |